Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
Haas NB, LaRiviere MJ, Buckingham TH, Cherkas Y, Calara-Nielsen K, Foulk B, Patel J, Gross S, Smirnov D, Vaughn DJ, Amaravadi R, Wellen KE, Savitch SL, Majmundar KJ, Black TA, Yee SS, He M, Min EJ, Long Q, Jones JO, Pal SK, Carpenter EL.
Haas NB, et al. Among authors: jones jo.
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):448-456. doi: 10.1038/s41391-020-00295-z. Epub 2020 Oct 2.
Prostate Cancer Prostatic Dis. 2021.
PMID: 33009489